HK Stock Market Move | XTALPI (02228) opened more than 4% higher, reaching a strategic collaboration in AI drug discovery with a renowned international pharmaceutical company for over 400 million US dollars.

XTALPI (02228) opened over 4% higher, rising 4.15% to 7.27 Hong Kong dollars as of the time of writing, with a trading volume of 13.0424 million Hong Kong dollars. On the news front, on the evening of June 9, XTALPI announced that the board of directors happily announced a strategic partnership with a well-known international biopharmaceutical company. The two parties will jointly develop innovative oral small molecule drugs with "Best in-Class" potential targeting a GPCR (G Protein-Coupled Receptor) target. This agreement is based on a rigorous and successful pilot phase, during which XTALPI integrated quantum physics and AI algorithms to achieve breakthrough hit rates, confirming the platform's ability to handle such complex metabolic targets. According to the agreement, the partner will make an upfront payment to XTALPI and bear all early-stage research and development costs. XTALPI will also receive milestone payments for preclinical, clinical, and commercialization, as well as future sales royalties, with a potential total amount exceeding 400 million US dollars. This collaboration model, which deeply links short-term research and development income with the long-term pipeline asset value, effectively reduces the cost and risk of XTALPI's participation in high-barrier target research and development, while also locking in the high elasticity return space for blockbuster drugs.